Scienture Holdings, Inc. SCNX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -74.67%
- 1 year
- -83.35%
- Open
- 3.13
- Prev close
- 3.22
- Mkt cap
- 5.31M
- Vol
- 6.13K
- Avg vol
- 193.40K
- EPS
- -52.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.13
- High
- 3.25
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.33
- Inst. own
- 1.33%
- Dividend
- 0.00
- Ex-div date
- Jul 18, 2024
- 50-d avg
- 7.66
- 200-d avg
- 9.36
- 1y target
- 0.00
News
4 days ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to…
5 days ago seekingalpha.com
Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript
Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript
-
1 week ago benzinga.com
Maxim Group Maintains Buy on Scienture Holdings, Adjusts Price Target To $6 (reverse stock split 1:25)
Maxim Group analyst Naz Rahman maintains Scienture Holdings (NASDAQ:SCNX) with a Buy, adjusts target to $6 from $37.5 (reverse stock split 1:25).
-
1 week ago benzinga.com
Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™Two FDA-Approved…
1 week ago globenewswire.com
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli ™ Growth and the Commercial Launch of REZENOPY ™
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
-
2 weeks ago benzinga.com
SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and…
2 weeks ago globenewswire.com
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth
2 weeks ago benzinga.com
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.
1 month ago globenewswire.com
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Major Institutional Formulary Win Expands Arbli ™ 's Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
1 month ago benzinga.com
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Three U.S. pediatric hospitals added Scienture's hypertension drug Arbli to their formularies, boosting institutional reach.
1 month ago benzinga.com
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corteva plunged 57% premarket.
1 month ago benzinga.com
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened
Scienture Holdings shares tumble 19% after hours following a newly announced 1-for-25 reverse stock split.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…
1 month ago globenewswire.com
Scienture Holdings, Inc. Announces Reverse Stock Split
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on…
-
1 month ago benzinga.com
SCIENTURE To Provide REZENOPY To Addiction Treatment Centers
Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United…
1 month ago globenewswire.com
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States
1 month ago globenewswire.com
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Management to Highlight Growing Commercial Momentum of Arbli ™ and the Commercial Launch of REZENOPY ™
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding…
-
2 months ago benzinga.com
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of…
2 months ago globenewswire.com
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million…
2 months ago globenewswire.com
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™
2 months ago benzinga.com
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
Scienture launches Rezenopy, a 10 mg naloxone nasal spray for opioid overdoses, fulfilling initial U.S. wholesale orders.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million. Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to…
3 months ago benzinga.com
Why WD-40 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
WD-40 Co (WDFC) shares rise sharply in pre-market trading after reporting better-than-expected third-quarter financial results.
3 months ago benzinga.com
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why
Scienture Holdings shares jumped 23.54% overnight after the company completed manufacturing inventory for the commercial launch of REZENOPY.
-
3 months ago benzinga.com
Scienture To Begin Shiptments Of REZENOPY Nasal Spray 10mg To U.S. Pharmaceutical Wholesalers Later This Month
The Company expects REZENOPY™ to become commercially available for purchase in August. The Company is working with its wholesale distribution partners in preparation for nationwide commercial…
3 months ago globenewswire.com
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray U. S. naloxone market totals ~$144 million in annual…
-
4 months ago benzinga.com
Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expanded Payor Coverage, Broader Pharmacy Access And New Channel Partnerships
The Company recently secured additional payor coverage representing approximately 12.5 million incremental covered lives, including expanded access through Medicare Part D supplement plans and other…
4 months ago globenewswire.com
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
-
4 months ago benzinga.com
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose
4 months ago globenewswire.com
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market
4 months ago benzinga.com
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
Scienture expands Rezenopy access through a major health plan ahead of launch, adding coverage for more than 100 million lives.
-
4 months ago benzinga.com
EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-July
5,000+ Healthcare Facilities Reached ThroughGPO Agreements, Covering ~60% of Institutional GPO MarketU.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units…
5 months ago accessnewswire.com
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced…
5 months ago globenewswire.com
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for…
5 months ago globenewswire.com
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing…
-
5 months ago benzinga.com
Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.22) by 63.64 percent. This is a 75.76 percent increase over losses of…
-
5 months ago benzinga.com
SCIENTURE HOLDINGS Secures $11M In Non-Dilutive Debt Financing Through Note Purchase Agreement With Institutional Investor
Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatmentFinancing also drives…
5 months ago globenewswire.com
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment
-
6 months ago benzinga.com
USPTO Issued SCIENTURE HOLDINGS U.S. Patent No. 12,605,365, Titled "Losartan Liquid Formulations and Methods of Use,"
U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension
6 months ago globenewswire.com
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
U. S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI as the first FDA-approved ready-to-use oral suspension COMMACK,…
-
6 months ago benzinga.com
Scienture Awarded $950K U.S. Department Of Veterans Affairs Pharmaceutical Supply Contract, Pharmaceutical Preparation Manufacturing
https://sam.gov/opp/cd98e3d515624c65afe83187b80993a7/view
-
6 months ago benzinga.com
SCIENTURE HOLDINGS Gets 180‑Day Nasdaq Extension; Compliance Deadline Now October 12
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and…
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
7 months ago benzinga.com
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025
Scienture reports 216% revenue growth in 2025, driven by Arbli uptake, patent wins, and expanded healthcare access across the US.
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session